An FDA warning has prompted LabCorp to stop sales of a controversial blood test for ovarian cancer. Experts have raised questions about whether OvaSure is effective. OvaSure had been offered without FDA approval because diagnostic checks are sometimes exempt from federal regulation if they are developed in a single laboratory. However, OvaSure was developed in conjunction with Yale University.
Hopefully, this gets sorted out quickly. If it is a good test, we want OvaSure on the market. But we have to test it to make sure it does not do more harm than good.